Artesunate/amodiaquine 100/270 mg WHOPAR part 5 03/2009, version 1.0 (Sanofi-Aventis) MA058 LABELING

Similar documents
Lamivudine Tablets 150 mg (Macleods Pharmaceuticals Ltd), HA424. WHOPAR Part 5 05/2011, version 1.0 LABELLING. Page 1 of 8

Sulfamethoxazole/Trimethoprim 400mg/80mg Tablets (Micro Labs Ltd), HA598. WHOPAR part 5 July 2017 LABELLING

Artesunate 120mg powder for injection (Guilin Pharmaceutical Co., Ltd), MA90 LABELLING. Page 1 of 6

Artesunate 60 mg for injection WHOPAR part 5 June 2013 (Guilin Pharmaceutical Co., Ltd.), MA051 LABELLING

Artemether 20mg/lumefantrine 120mg WHOPAR part 5 12/2011 Dispersible tablets (Novartis Pharma AG), MA069 LABELLING. Page 1 of 6

WHOPAR part 5 Suppliers submission of the SRA approved text

JSC «Olainfarm», Latvia PAS-Na 5.52 g Powder for oral solutions

PATIENT INFORMATION LEAFLET

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX III LABELLING AND PACKAGE LEAFLET

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

PATIENT INFORMATION LEAFLET

WHOPAR Part 3 March Zinc (as sulfate monohydrate) 20 mg Tablets (Macleods Pharmaceuticals Ltd), DI005 PACKAGE LEAFLET.

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/17

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

Artesunate 60 mg for injection WHOPAR part 3 November 2015 (Guilin Pharmaceutical Co., Ltd.), MA051 PATIENT INFORMATION LEAFLET

PART 1.B SPC, LABELLING AND PACKAGE LEAFLET

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

B. PACKAGE LEAFLET. Page 1 of 6

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/16

PART 1 B SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

PATIENT INFORMATION LEAFLET

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

NL/H/1291/ /DC PACKAGE LEAFLET. Annex 3 PL.doc 0

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Artecef 50/Artecef 150 (ARTECEF BV) WHOPAR part 4 09/2008, version 1.0 MA027/028 SUMMARY OF PRODUCT CHARACTERISTICS. Page 1 of 7

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Artesunate 50 mg tablets (Guilin), MA044 WHOPAR part 4 02/2009, version 1.0 Section 3 & 6 updated : June 2017 SUMMARY OF PRODUCT CHARACTERISTICS

B. PACKAGE LEAFLET 1

Metoclopramide hydrochloride mg (Quantity corresponding to anhydrous metoclopramide hydrochloride) mg

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Pyrazinamide 500 mg Tablets (Macleods Pharmaceuticals Ltd), TB243. WHOPAR part 3 April 2014 Section 6 updated: May 2014 PACKAGE LEAFLET.

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Proctosedyl Ointment Hydrocortisone/Cinchocaine hydrochloride/framycetin sulphate/aesculin

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. PolyVar Yellow. Summary of Product Characteristics (SPC)

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SCIENTIFIC DISCUSSION. AkuriT-3 Tablets*

Ventolin Accuhaler 200 micrograms salbutamol sulfate

SUMMARY OF PRODUCT CHARACTERISTICS

B. PATIENT INFORMATION LEAFLET

Artesunate 60 mg for injection WHOPAR part 3 June 2013 (Guilin Pharmaceutical Co., Ltd.), MA051 PATIENT INFORMATION LEAFLET

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Neuro-Medivitan is a vitamin preparation. Intended use Systemic neurological disorders due to proven deficiency of vitamins B1 and B6.

PATIENT INFORMATION LEAFLET

Paul-Ehrlich-Institut DE/V/0022/001/II/023/G Page 1

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

Package leaflet: Information for the user. Carmellose sodium

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for the user. Catacrom 2 % w/v Eye Drops, Solution. Sodium cromoglicate

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

[Version 8.1,01/2017] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Transcription:

LABELING 1

PARTICULARS TO APPEAR ON THE OUTER PACKAGING Carton box 25 blisters of 3 tablets 1. NAME OF THE MEDICINAL PRODUCT ARTESUNATE AMODIAQUINE WINTHROP 100mg / 270mg Tablets* 2. STATEMENT OF ACTIVE SUBSTANCE(S) Artesunate...100.00 mg Amodiaquine base...270.00 mg (in the form of amodiaquine hydrochloride)...352.64 mg 3. LIST OF EXCIPIENTS 4. PHARMACEUTICAL FORM AND CONTENTS 25 blisters of 3 tablets 5. METHOD AND ROUTE(S) OF ADMINISTRATION Oral route Read the package leaflet before use. 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN Keep out of the reach and sight of children. 7. OTHER SPECIAL WARNING(S), IF NECESSARY 8. EXPIRY DATE EXP {MM/YYYY} 9. SPECIAL STORAGE CONDITIONS Store below 30 C * Trade names are not prequalified by WHO. This is under local DRA responsibility. Throughout this WHOPAR the proprietary name is given as an example only. 2

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 11. NAME AND ADDRESS OF THE SUPPLIER Sanofi-aventis 82 avenue Raspail 94250 Gentilly France 12. WHO REFERENCE NUMBER (PREQUALIFICATION PROGRAMME) MA058 13. BATCH NUMBER Batch { } 14. (ADVICE ON) GENERAL CLASSIFICATION FOR SUPPLY Medicinal product subject to medical prescription 15. INSTRUCTIONS ON USE 3

PARTICULARS TO APPEAR ON THE OUTER PACKAGING Carton box 25 blisters of 6 tablets 1. NAME OF THE MEDICINAL PRODUCT ARTESUNATE AMODIAQUINE WINTHROP 100mg / 270mg Tablets 2. STATEMENT OF ACTIVE SUBSTANCE(S) Artesunate...100.00 mg Amodiaquine base...270.00 mg (in the form of amodiaquine hydrochloride)...352.64 mg 3. LIST OF EXCIPIENTS 4. PHARMACEUTICAL FORM AND CONTENTS 25 blisters of 6 tablets 5. METHOD AND ROUTE(S) OF ADMINISTRATION Oral route Read the package leaflet before use. 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN Keep out of the reach and sight of children. 7. OTHER SPECIAL WARNING(S), IF NECESSARY 8. EXPIRY DATE EXP {MM/YYYY} 9. SPECIAL STORAGE CONDITIONS Store below 30 C 4

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 11. NAME AND ADDRESS OF THE SUPPLIER Sanofi-aventis 82 avenue Raspail 94250 Gentilly France 12. WHO REFERENCE NUMBER (PREQUALIFICATION PROGRAMME) MA058 13. BATCH NUMBER Batch { } 14. (ADVICE ON) GENERAL CLASSIFICATION FOR SUPPLY Medicinal product subject to medical prescription 15. INSTRUCTIONS ON USE 5

PARTICULARS TO APPEAR ON THE OUTER PACKAGING Carton box 1 blister of 3 tablets 1. NAME OF THE MEDICINAL PRODUCT ARTESUNATE AMODIAQUINE WINTHROP 100mg / 270 mg Tablets 2. STATEMENT OF ACTIVE SUBSTANCE(S) Artesunate...100.00 mg Amodiaquine base...270.00 mg (in the form of amodiaquine hydrochloride)...352.64 mg 3. LIST OF EXCIPIENTS 4. PHARMACEUTICAL FORM AND CONTENTS 1 blister of 3 tablets 5. METHOD AND ROUTE(S) OF ADMINISTRATION Oral route Read the package leaflet before use. 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN Keep out of the reach and sight of children. 7. OTHER SPECIAL WARNING(S), IF NECESSARY 8. EXPIRY DATE EXP {MM/YYYY} 9. SPECIAL STORAGE CONDITIONS Store below 30 C. 6

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 11. NAME AND ADDRESS OF THE SUPPLIER Sanofi-aventis + 82 avenue Raspail 94250 Gentilly France 12. WHO REFERENCE NUMBER (PREQUALIFICATION PROGRAMME) MA058 13. BATCH NUMBER Batch { } 14. (ADVICE ON) GENERAL CLASSIFICATION FOR SUPPLY Medicinal product subject to medical prescription 15. INSTRUCTIONS ON USE 7

PARTICULARS TO APPEAR ON THE OUTER PACKAGING Carton box 1 blister of 6 tablets 1. NAME OF THE MEDICINAL PRODUCT ARTESUNATE AMODIAQUINE WINTHROP 100mg / 270 mg Tablets 2. STATEMENT OF ACTIVE SUBSTANCE(S) Artesunate...100.00 mg Amodiaquine base...270.00 mg (in the form of amodiaquine hydrochloride)...352.64 mg 3. LIST OF EXCIPIENTS 4. PHARMACEUTICAL FORM AND CONTENTS 1 blister of 6 tablets 5. METHOD AND ROUTE(S) OF ADMINISTRATION Oral route Read the package leaflet before use. 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN Keep out of the reach and sight of children. 7. OTHER SPECIAL WARNING(S), IF NECESSARY 8. EXPIRY DATE EXP {MM/YYYY} 9. SPECIAL STORAGE CONDITIONS Store below 30 C. 8

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 11. NAME AND ADDRESS OF THE SUPPLIER Sanofi-aventis + 82 avenue Raspail 94250 Gentilly France 12. WHO REFERENCE NUMBER (PREQUALIFICATION PROGRAMME) MA058 13. BATCH NUMBER Batch { } 14. Advice on GENERAL CLASSIFICATION FOR SUPPLY Medicinal product subject to medical prescription 15. INSTRUCTIONS ON USE 9

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS Aluminium/aluminium blister 1. NAME OF THE MEDICINAL PRODUCT ARTESUNATE AMODIAQUINE WINTHROP 100mg / 270mg Tablets 2. NAME OF THE SUPPLIER Sanofi-Aventis 3. EXPIRY DATE EXP {MM/YYYY} 4. BATCH NUMBER Batch { } 10